Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 14, 2014; 20(38): 13791-13803
Published online Oct 14, 2014. doi: 10.3748/wjg.v20.i38.13791
Published online Oct 14, 2014. doi: 10.3748/wjg.v20.i38.13791
Potential prognostic, diagnostic and therapeutic markers for human gastric cancer
Ming-Ming Tsai, Department of Nursing, Chang-Gung University of Science and Technology, Taoyuan 333, Taiwan
Chia-Siu Wang, Department of General Surgery, Chang Gung Memorial Hospital at Chiayi, Taoyuan 613, Taiwan
Chung-Ying Tsai, Hsiang-Cheng Chi, Yi-Hsin Tseng, Kwang-Huei Lin, Department of Biochemistry, College of Medicine, Chang-Gung University, Taoyuan 333, Taiwan
Author contributions: Tsai MM, Tsai CY, Chi HC and Tseng YH have substantial contributions to the conception and design, and acquisition of data; Tsai MM wrote and prepared the manuscript; Tsai MM, Wang CS and Lin KH revised the manuscript critically for important intellectual content; Lin KH approved the final version to be published.
Supported by Grants from Chang Gung Memorial Hospital, Taoyuan, Taiwan, No. CMRPF1C0151 and No. CMRPG6D0011
Correspondence to: Kwang-Huei Lin, PhD, Professor, Department of Biochemistry, College of Medicine, Chang-Gung University, 259 Wen-Hwa 1st Road, Kweisan, Taoyuan 333, Taiwan. khlin@mail.cgu.edu.tw
Telephone: +886-3-2118263 Fax: +886-3-2118263
Received: February 28, 2014
Revised: April 18, 2014
Accepted: May 26, 2014
Published online: October 14, 2014
Revised: April 18, 2014
Accepted: May 26, 2014
Published online: October 14, 2014
Core Tip
Core tip: Serum-based gastric cancer tumor markers and their clinical significance or application are discussed. Serum-based carcinoembryonic antigen, carbohydrate antigen 19-9 and carbohydrate antigen 72-4 and tissue-based human epidermal growth factor receptor 2/Neu are potential tumor markers for various types of gastrointestinal cancer. This review provides a brief description of various tumor markers for the purposes of diagnosis, prognosis and therapeutics, and we include markers already in clinical practice and various forthcoming biomarkers. Hopefully, based on the markers, we will generate accurate diagnoses, prognoses and select the most appropriate therapy.